Aurionpro Solutions, Muthoot Finance, Gravita India, Lloyds Metals, Goldiam Int'l, Cipla, Persistent Systems: Top buzzing stocks

At 12:56 PM, the S&P BSE SENSEX was trading at 75,386.44, up 1,539.29 points, or 2.08%, while the NSE's NIFTY50 index was trading at 22,904.30, up 505.15 points, or 2.26%.

Analysts say that Indian metal companies are likely to benefit from relatively lower tariffs on India compared to China's massively higher tariffs.

Goldiam International is a global exporter of diamond jewellery, including to major retailers, department stores, and wholesalers in the US market. Goldiam even has a dedicated sales office in New York.

The NIFTY PHARMA index was trading 2.64% higher. Out of 20 constituents, 19 were trading in the green and one in the red.

Laurus Labs was the top gainer – up by 7% – followed by Granules India and Divi's Lab – up 4.41% and 3.93%, respectively.

Cipla shares rallied as much as 5.14% to ₹1,488.50 apiece on the NSE after the company said it had received a nod from the United States Food and Drug Administration (USFDA) for its breast cancer drug.

The Indian IT services sector is not directly hit by Trump's tariff order on goods, but there could be worrisome indirect bearings on it arising out of a possible slowdown in decision-making and GDP growth in America over higher tariffs, which may then cloud demand from specific verticals.

When last seen, the NIFTY IT index was trading 1.32% higher, with all 10 constituents trading in the green.

The biggest gainers were Persistent Systems (up 3.55%), followed by Mphasis (up 3.25%) and LTIMindtree (up 3%).

The company will pay ₹23 crore, including fixed and performance-based considerations for this acquisition, while the acquisition shall be completed within 30 days from the date of execution of the SPA.

Aurionpro stated that the acquisition is part of its strategy to deliver an integrated front-to-back solution for cash and trade management. The collaboration will streamline operations and strengthen the company’s value proposition in corporate banking through its client institutions.

The stock soared as much as 5.45% to ₹323 per share on the National Stock Exchange (NSE).

In an exchange filing on April 10, the company informed that its subsidiary, Biocon Biologics, has received a nod from the US FDA to market a cancer treatment biosimilar product.